Microgravity Associated Bone Loss-B (MABL-B)
Principal Investigator(s):
- Abba Zubair, M.D., Ph.D., Mayo Clinic
Overview: Microgravity Associated Bone Loss-B (MABL-B) tests potential treatments to prevent bone loss in astronauts by examining how microgravity affects bone-forming and bone-degrading cells. The investigation focuses on blocking IL-6 protein signaling pathways that may contribute to bone deterioration in space.
Science objectives:
- Evaluate the impact of microgravity on mesenchymal stem cell bone remodeling processes
- Test IL-6 signaling pathway inhibitors as potential countermeasures against bone loss
- Determine how blocking specific cellular communication pathways affects bone formation and breakdown in microgravity
Potential Earth applications:
- Could lead to new treatments for age-related bone loss and osteoporosis
- May advance understanding of cellular mechanisms behind bone diseases
Potential space applications:
- May lead to pharmacological countermeasures to protect astronaut bone health on long-duration missions
- Could inform medical protocols for Moon and Mars exploration where emergency return to Earth is not possible
- May contribute to development of preventive treatments for deep space missions
Related resources:
Microgravity Associated Bone Loss-B (MABL-B)
Microgravity Associated Bone Loss-A (MABL-A)
Bone Loss Research Launches Aboard NASA’s SpaceX-33 Resupply Mission